Outcome

The findings of this study provide promising insights into the potential of hyperbaric oxygen therapy (HBOT) as a treatment for high blood pressure. Conducted with normotensive Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) the study demonstrated significant reductions in both systolic blood pressure (SBP) and diastolic blood pressure (DBP) following a regimen of 6 hours per day of HBOT over an 8-week period.

Introduction

This study investigates the effects of hyperbaric oxygen therapy (HBOT) on blood pressure and oxidative stress in both normotensive and hypertensive rats. The research was conducted on Wistar-Kyoto rats (WKY) with normal blood pressure and spontaneously hypertensive rats (SHR) both groups were exposed to increased atmospheric pressure (950 mmHg) and oxygen concentration (36%) for 6 hours daily over an 8-week period. The results demonstrated significant reductions in systolic blood pressure (SBP) in WKY rats after 5 weeks of HBOT without affecting diastolic blood pressure (DBP). In SHR rats both SBP and DBP were significantly reduced after 3 and 7 weeks of therapy. Additionally HBOT was found to lower levels of reactive oxygen metabolites (dROMs) indicating reduced oxidative stress in both rat types. The SHR group also showed higher biological antioxidant potentials (BAPs) suggesting enhanced antioxidant capacity with HBOT. These findings suggest that HBOT might be effective in lowering blood pressure and reducing oxidative stress in hypertensive conditions.

Results

The study investigated the effects of hyperbaric oxygen therapy (HBOT) on blood pressure and oxidative stress markers in normotensive Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR). The research involved subjecting the rats to an environment with elevated atmospheric pressure (950 mmHg) and increased oxygen concentration (36%) for 6 hours daily over an 8-week period.

The key findings showed significant reductions in systolic blood pressure (SBP) and diastolic blood pressure (DBP) in both WKY and SHR groups subjected to HBOT. In the WKY rats a decrease in SBP was observed after five weeks of treatment compared to the control group with no significant change noted in DBP. In contrast SHR rats exhibited reductions in both SBP and DBP as early as three weeks with sustained effects observed at the seven-week mark.

Additionally HBOT was associated with a decrease in levels of reactive oxygen metabolites (dROMs) in both the WKY and SHR groups indicative of reduced oxidative stress. Furthermore the SHR group receiving HBOT also displayed higher biological antioxidant potentials (BAPs) suggesting an enhancement in antioxidant capacity a change not seen in the WKY group.

These findings highlight the potential of HBOT to effectively lower blood pressure and reduce oxidative stress particularly in hypertensive conditions suggesting a dual mechanism of action involving both blood pressure regulation and oxidative stress mitigation.

Conclusion

In conclusion this study highlights the potential efficacy of hyperbaric oxygen therapy (HBOT) in managing hypertension evidenced by significant reductions in both systolic and diastolic blood pressures in spontaneously hypertensive rats (SHR) and systolic blood pressure in normotensive Wistar-Kyoto rats (WKY). Furthermore the observed decrease in reactive oxygen metabolites (dROMs) and the increased biological antioxidant potentials (BAPs) in the SHR group suggest that HBOT may reduce oxidative stress and enhance antioxidant defenses contributing to its antihypertensive effects.

These findings suggest that HBOT might offer a dual therapeutic approach for hypertension by not only lowering blood pressure but also ameliorating oxidative stress which is often a contributory factor in cardiovascular diseases. The implications of this research extend to the potential development of HBOT as a non-pharmacological intervention that could complement existing hypertension treatments. Future investigations should aim to elucidate the precise mechanisms by which HBOT exerts these beneficial effects and explore the applicability of these findings in human clinical trials to confirm safety and effectiveness in hypertensive patients.